Acquisition of Raven biotechnologies, inc.
Our attorneys represented MacroGenics, Inc., a privately held biotechnology company based in Rockville, Maryland, in its acquisition of Raven biotechnologies, inc., a South San Francisco, California-based biotechnology company. Under the all-stock transaction, which closed in July 2008, Raven will be a wholly owned subsidiary of MacroGenics. The acquisition of Raven's cancer stem cell program will allow MacroGenics, which works to develop immunotherapeutics, including monoclonal antibodies, to treat patients with cancer, autoimmune disorders, allergy, and infectious diseases, to diversify and increase its production of lead therapeutic candidates in the area of oncology discovery, which is one of the most scientifically and commercially promising areas of drug development, and thereby expand its pursuit of collaborations and strategic alliances with pharmaceutical and other biotechnology companies. The firm handled all aspects of the transaction, including corporate and securities, regulatory, tax, employee benefits, employment, intellectual property, real estate and environmental matters.